Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that Henrik Damkjær Simonsen has been appointed Chief Financial Officer, as of April 1, 2023. He succeeds Peter Åkerlund who has been acting CFO since November 16 of this year.
Henrik Damkjær Simonsen has more than 30 years of experience from various senior roles in the life science industry, both on the banking and on the business side. He comes from a position as Finance Director at SAGA Diagnostics AB and has previously worked as CFO at Nuevolution AB and as Head of Life Science, Corporate Finance at SEB, among others.
"I am very much looking forward to welcoming Henrik to the team at Iconovo. His comprehensive experience from the capital markets in general and life science companies in particular, is an excellent fit as we work to establish Iconovo as a global leader in inhalation treatments," says Johan Wäborg, CEO of Iconovo.